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Preamble 
It is becoming more apparent each day that despite a strong 
national commitment to excellence in health care, the re-
sources and personnel are finite. It is, therefore, appropriate 
that the medical profession examine the impact of develop-
ing technology on the practice and cost of medical care. 
Such analysis, carefully conducted, could potentially have 
an impact on the cost of medical care without diminishing 
the effectiveness of that care. 
To this end, the American College of Cardiology and the 
American Heart Association in 1980 established a Task 
Force on Assessment of Diagnostic and Therapeutic Cardio-
vascular Procedures with the following charge: 
The Task Force of the American College of Cardiology and 
the American Heart Association shall define the role of 
specific noninvasive and invasive procedures in the diag-
nosis and management of cardiovascular disease. 
The Task Force shall address, when appropriate, the contri-
bution, uniqueness, sensitivity, specificity, indications, 
contraindications and cost-effectiveness of such specific 
procedures. 
The Task Force shall include a Chairman and six members, 
three representatives from the American Heart Associa-
tion and three representatives from the American College 
of Cardiology. The Task Force may select ad hoc mem-
bers as needed upon the approval of the Presidents of both 
organizations. Recommendations of the Task Force are 
forwarded to the President of each organization. 
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The members of the Task Force are: George A. 
Beller, MD, Roman W. DeSanctis, MD, Harold T. Dodge, 
MD, J. Ward Kennedy, MD, T. Joseph Reeves, MD, Sylvan 
Lee Weinberg, MD and Charles Fisch, MD, Chairman. 
This document was reviewed by the officers and other 
responsible individuals of the two organizations and re-
ceived final approval in March 1991. It is being published 
simultaneously in Circulation and the Journal of the Amer-
ican College of Cardiology. The potential impact of this 
document on the practice of cardiology and some of its 
unavoidable shortcomings are clearly set out in the introduc-
tion. 
Charles Fisch, MD, F ACC 
I. Introduction 
This is a revision of the 1984 Guidelines for Permanent 
Cardiac Pacemaker Implantation (l ,2). The Joint Subcom-
mittee of the American College of Cardiology and American 
Heart Association was chaired by Robert L. Frye, MD and, 
in addition to the members of the Joint Task Force, included 
the following ad hoc members: John J. Collins, MD, Leon-
ard S. Dreifus, MD, Leonard S. Gettes, MD, Paul C. 
Gillette, MD and Victor Parsonnet, MD. The present docu-
ment was reviewed by selected consultants; S. Serge Barold, 
MD, John D. Fisher, MD, Roger A. Freeman, MD, Richard 
M. Luceri, MD, Seymour Furman, MD, and Melvin M. 
Scheinman, MD. Many of their suggestions have been 
incorporated in the final text. 
Indications for Permanent Cardiac Pacemakers 
and Antitachycardia Devices 
These recommendations are the subject of this report. 
Because of the multitude, complexity and initial cost of 
currently available pacing systems, the Committee has in-
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cluded recommendations regarding selection of devices for 
specific clinical problems in which pacing or defibrillation is 
indicated. The Committee recommendations are based on 
current evidence in relation to both knowledge of the natural 
history of disorders of cardiac rhythm, as well as the 
characteristics of currently available devices. Because of 
continuing research and development, some of these recom-
mendations may be subject to further modification in the 
future. 
These recommendations apply to permanent pacing and 
antitachycardia devices in the management of chronic, 
though sometimes intermittent, disorders of cardiac rhythm. 
For the most part, they do not pertain to identifiable factors 
that cause transient depression of cardiac impulse formation 
and conduction, such as drugs, electrolyte or endocrine 
imbalances, infection or the acute phase of myocardial 
infarction. The decision to implant a pacemaker or anti-
tachycardia device must be reached by scrupulous adher-
ence to a fundamental principle of clinical medicine: the 
demand for careful, thoughtful analysis of each patient. 
Attention must be given to the general medical, emotional 
and mental state of the patient, as well as to the specifics of 
the cardiac rhythm disturbance before a proper management 
decision can be made. 
The Committee has not offered any recommendations 
regarding resources required to perform pacemaker or anti-
tachycardia device insertions, training of individuals for this 
purpose or the appropriate follow-up and monitoring of 
patients with permanent pacemakers. These critically impor-
tant topics have been addressed elsewhere (3). The Commit-
tee unanimously urges careful review and adoption of the 
resource guidelines by all institutional administrators, phy-
sicians and surgeons who are responsible for antitachycardia 
device therapy. 
The clinical symptoms associated with bradycardia need 
definition at the outset because they recur throughout the 
report as major indications for permanent pacemaker ther-
apy. In this report, the term "symptomatic bradycardia" 
refers to the following clinical manifestations that are di-
rectly attributable to the slow heart rate: transient dizziness, 
light-headedness, near syncope or frank syncope as mani-
festations of transient cerebral ischemia and more general-
ized symptoms such as marked exercise intolerance or frank 
congestive heart failure. It is acknowledged, however, that 
some patients may have been symptomatic only in retro-
spect. How to recognize these individuals a priori is not 
within the scope of this document. As is mentioned else-
where, it must be assumed that physicians who implant 
anti tachycardia devices are experts and will be skillful 
enough to make this distinction. 
Indications for permanent pacemakers have been 
grouped according to the following classifications: 
Class I: Conditions for which there is general agreement 
that permanent pacemakers or antitachycardia 
devices should be implanted. 
Class II: Conditions for which permanent pacemakers or 
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anti tachycardia devices are frequently used but 
there is divergence of opinion with respect to the 
necessity of their insertion. 
Class III: Conditions for which there is general agreement 
that pacemakers or antitachycardia devices are 
unnecessary . 
In those patients being considered for pacemakers or 
antitachycardia devices, decision making may be influenced 
by the following additional factors: 
1. Overall physical and mental state of the patient, includ-
ing the absence of associated diseases that may result 
in a limited quality or prognosis for life. 
2. Presence of associated underlying cardiac disease that 
may be affected adversely by bradycardia. 
3. Desire of the patient to operate a motor vehicle. 
4. Remoteness of medical care, including patients who 
travel widely or live alone who therefore might be 
unable to seek medical help if serious symptoms arise. 
5. Necessity for administering medication that may de-
press escape heart rates or aggravate atrioventricular 
(AV) block. 
6. Slowing of the basic escape rates. 
7. Significant cerebrovascular disease that might result in 
a stroke if cerebral perfusion were to suddenly de-
crease. 
S. Desires of the patient and family. 
This report provides brief definitions and descriptions of 
specific clinical situations in which pacing may be consid-
ered and literature references that document the basis for the 
recommendation. 
II. Pacing in Acquired A V Block in Adults 
Atrioventricular block is classified as first degree, second 
degree or third degree (complete) heart block; anatomically, 
it is defined as supra-His, intra-His and infra-His. Second 
degree heart block may be further classified as type I 
(progressive prolongation of PR interval before a blocked 
beat) or type II (no progressive prolongation of PR interval 
before blocked beats) and is usually associated with a wide 
QRS complex. Advanced second degree block refers to the 
block of two or more consecutive P waves. Patients with 
abnormalities of A V conduction may be asymptomatic or 
they may experience serious symptoms related to profound 
bradycardia or ventricular arrhythmias, or both. Decisions 
regarding the need for a pacemaker are influenced most 
importantly by the presence or absence of symptoms that are 
directly attributable to bradycardia. It is clearly documented 
(4-S) that patients with complete heart block and syncope 
have an improved survival with permanent pacing. There is 
no evidence to suggest that survival is prolonged with 
pacemakers in patients with isolated first degree A V block. 
The prognosis in type I second degree A V block, when due 
to AV node delay, tends to be benign (9-11). However, in 
patients with type II second degree AV block (either intra- or 
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infra-His), symptoms are frequent, prognosIs IS compro-
mised and progression to complete heart block is common 
(9,11,12). 
Recommendations for inserting a permanent pacemaker 
in patients with A V block with acute myocardial infarction 
or congenital A V block are discussed in a separate section. 
Atrioventricular block in the presence of supraventricular 
tachyarrhythmia does not constitute an indication for pace-
maker insertion except as specifically defined in the recom-
mendations that follow. 
Indications for Permanent Pacing in Acquired 
A V Block in Adults 
Class I 
A. Complete heart block, permanent or intermittent, at 
any anatomic level, associated with anyone of the 
following complications: 
1. Symptomatic bradycardia (discussed in the Intro-
duction). In the presence of complete heart 
block, symptoms must be presumed to be due to 
the heart block unless proved to be otherwise. 
2. Congestive heart failure. 
3. Ectopic rhythms and other medical conditions 
that require drugs that suppress the automaticity 
of escape pacemakers and result in symptomatic 
bradycardia. 
4. Documented periods of asystole ~3.0 s or any 
escape rate <40 beats/min in symptom-free pa-
tients. 
5. Confusional states that clear with temporary pac-
ing. 
6. Post AV junction ablation, myotonic dystrophy. 
B. Second degree A V block, permanent or intermittent, 
regardless of the type or the site of block, with 
symptomatic bradycardia. 
C. Atrial fibrillation, atrial flutter or rare cases of su-
praventricular tachycardia with complete heart 
block or advanced A V block, bradycardia and any of 
the conditions described under IA. The bradycardia 
must be unrelated to digitalis or drugs known to 
impair A V conduction. 
Class II 
A. Asymptomatic complete heart block, permanent or 
intermittent, at any anatomic site, with ventricular 
rates of 40 beats/min or faster. 
B. Asymptomatic type II second degree A V block, 
permanent or intermittent. 
C. Asymptomatic type I second degree A V block at 
intra-His or infra-His levels. 
Class III 
A. First degree A V block (see section IV on bifascicu-
lar and trifascicular block). 
B. Asymptomatic type I second degree A V block at the 
supra-His (A V node) level. 
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III. Pacing in Atrioventricular (A V) Block 
Associated With Myocardial Infarction 
3 
Indications for permanent pacing after myocardial infarc-
tion in patients experiencing A V block are related in large 
measure to the presence of intraventricular conduction de-
fects. The requirement for temporary pacing in acute myo-
cardial infarction does not by itself constitute an indication 
for permanent pacing. The long-term prognosis in survivors 
of acute myocardial infarction who have had A V block is 
related primarily to the extent of myocardial injury and the 
character of intraventricular conduction disturbances rather 
than to the AV block itself (6,13-16). Patients with acute 
myocardial infarction who have intraventricular conduction 
defects, with the exception of isolated left anterior 
hemiblock, have an unfavorable short- and long-term prog-
nosis and an increased incidence of sudden death (12-14). 
This unfavorable prognosis is not necessarily due to the 
development of high grade A V block, although the incidence 
of such block is higher in postinfarction patients with abnor-
mal intraventricular conduction (14,17). Unlike some other 
indications for permanent pacing, the criteria in patients with 
myocardial infarction and A V block do not necessarily 
depend on the presence of symptoms. 
Indications for Permanent Pacing After 
Myocardial Infarction 
Class I 
A. Persistent advanced second degree A V block or 
complete heart block after acute myocardial infarc-
tion (12-14) with block in the His-Purkinje system 
(bilateral bundle branch block) (14-17). 
B. Patients with transient advanced AV block and 
associated bundle branch block (14,15). 
Class II 
A. Patients with persistent advanced block at the A V 
node (18). 
Class III 
A. Transient A V conduction disturbances in the ab-
sence of intraventricular conduction defects (14). 
B. Transient AV block in the presence of isolated left 
anterior hemiblock (13). 
C. Acquired left anterior hemiblock in the absence of 
AV block. 
D. Patients with persistent first degree A V block in the 
presence of bundle branch block not demonstrated 
previously (14). 
IV. Pacing in Bifascicular and Trifascicular 
Block (Chronic) 
Bifascicular and trifascicular block refer to electrocardio-
graphic (ECG) evidence of impaired conduction below the 
A V node in two or three of the fascicles of the right and left 
bundles. In patients with such ECG abnormalities, there is 
convincing evidence that advanced heart block with symp-
4 DREIFUS ET AL. 
ACC/AHA TASK FORCE REPORT 
toms due to the block is associated with a high death rate and 
a significant incidence of sudden death (5,19). 
Syncope is common in patients with bifascicular block. 
Usually it is not recurrent or associated with an increased 
incidence of sudden death (20-32). It has been suggested 
that pacing relieves the transient neurologic symptoms, but 
does not reduce the frequency of sudden death (23). How-
ever, there is convincing evidence (5) that in the presence of 
permanent or transient complete heart block, syncope is 
associated with an increased incidence of sudden death. 
Thus, being unable to define the cause of syncope in the 
presence of bifascicular or trifascicular block, it appears 
reasonable to assume that the syncope may be due to 
transient complete heart block and, thus, in the opinion of 
some investigators (24,25), prophylactic permanent pacing is 
indicated. 
Although complete heart block is most often preceded by 
bifascicular block, the evidence is impressive that the rate of 
progression of bifascicular block to complete heart block is 
low. Furthermore, no single clinical or laboratory variable, 
including bifascicular block, identifies patients at high risk of 
death from a future bradyarrhythmia due to the bundle 
branch block (26). 
Of the many laboratory variables, the PR and HV inter-
vals have been singled out as possible predictors of complete 
heart block and sudden death. Evidence indicates that PR 
interval prolongation is common in patients with bifascicular 
block. However, the prolongation is often at the level of the 
AV node. Furthermore, there is no correlation between the 
PR and HV intervals or between the length of the PR interval 
and progression to complete heart block and incidence of 
sudden death (27,28,32). Although most patients with 
chronic or intermittent complete heart block demonstrate 
prolongation of the HV interval during anterograde conduc-
tion, some investigators (30,31) have suggested that asymp-
tomatic patients with bifascicular block and a prolonged HV 
interval should be considered for permanent pacing, espe-
cially if the HV interval is ~IOO ms (32). The evidence 
indicates that although the prevalence of prolonged HV is 
high, the incidence of progression to complete heart block is 
low. HV prolongation accompanies advanced cardiac dis-
ease and is associated with an increased death rate; death is 
not sudden and is due to the underlying heart disease and not 
to complete heart block (20,23,26,27,32,33). 
Atrial pacing as a means of identifying patients at in-
creased risk of future complete heart block probably is not 
justified. The chance of inducing distal heart block with 
pacing is low (20,31,34,35). In fact, pacing often fails to 
induce distal His block in patients with documented abnor-
mal conduction of the His-Purkinje system (20,30,31,36,37). 
Furthermore, failure to induce distal block cannot be taken 
as evidence that the patient will not develop complete heart 
block. However, if atrial pacing induces infra-His block, 
some consider this to be an indication for pacing (38). 
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Indications for Permanent Pacing in 
Bifascicular and Trifascicular Block 
Class I 
A. Bifascicular block with intermittent complete heart 
block associated with symptomatic bradycardia (as 
defined). 
B. Bifascicular or trifascicular block with intermittent 
type II second degree A V block without symptoms 
attributable to the heart block. 
Class II 
A. Bifascicular or trifascicular block with syncope that 
is not proved to be due to complete heart block, but 
other possible causes for syncope are not identifi-
able. 
B. Markedly prolonged HV (> 100 ms) (32). 
c. Pacing-induced infra-His block (38). 
Class III 
A. Fascicular block without A V block or symptoms. 
B. Fascicular block with first degree A V block without 
symptoms. 
V. Pacing in Sinus Node Dysfunction 
Sinus node dysfunction (sick sinus syndrome) constitutes 
a spectrum of cardiac arrhythmias, including sinus bradycar-
dia, sinus arrest, sinoatrial block and paroxysmal supraven-
tricular tachycardia alternating with periods of bradycardia 
or even asystole. Patients with this condition may be symp-
tomatic from paroxysmal tachycardia, bradycardia, or both. 
Correlation of symptoms with the specific arrhythmias is 
essential, although this may be difficult, because of the 
intermittent nature of the episodes. Sinus bradycardia is 
accepted as a physiologic finding in trained athletes, who not 
uncommonly have heart rates of 40 to 50 beats/min while at 
rest and awake and may have sleeping rates as slow as 30 to 
43 beats/min with sinus pauses or type I A V block producing 
asystolic intervals as long as 1.6 to 2.8 s (39-41). These 
characteristics are due to increased vagal tone. Permanent 
pacing in patients with sinus node dysfunction may not 
necessarily result in improved survival time (42,43), but 
severe symptoms related to bradycardia may be relieved 
(44,45). 
Indications for Permanent Pacing in Sinus 
Node Dysfunction 
Class I 
A. Sinus node dysfunction with documented sympto-
matic bradycardia. In some patients this will occur 
as a consequence of long-term (essential) drug ther-
apy of a type and dose for which there are no 
acceptable alternatives. 
Class II 
A. Sinus node dysfunction, occurring spontaneously or 
as a result of necessary drug therapy, with heart 
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rates <40 beats/min when a clear association be-
tween significant symptoms consistent with brady-
cardia and the actual presence of bradycardia has 
not been documented. 
Class III 
A. Sinus node dysfunction in asymptomatic patients, 
including those in whom substantial sinus bradycar-
dia (heart rate <40 beats/min) is a consequence of 
long-term drug treatment. 
B. Sinus node dysfunction in patients in whom symp-
toms suggestive of bradycardia are clearly docu-
mented not to be associated with a slow heart rate. 
VI. Pacing in Hypersensitive Carotid Sinus 
and Neurovascular Syndromes 
The hypersensitive carotid sinus syndrome is defined as 
syncope resulting from an extreme reflex response to carotid 
sinus stimulation. It is an uncommon cause of syncope. 
There are two components of the reflex: 
1. Cardioinhibitory, resulting from increased parasympa-
thetic tone and manifested by slowing of the sinus rate 
or prolongation of the PR interval and advanced A V 
block, alone or in combination. 
2. Vasodepressor, secondary to a reduction in sympa-
thetic activity resulting in hypotension. 
Before concluding that permanent pacing is clinically 
indicated, the physician must determine the relative contri-
bution of the two components of carotid sinus stimulation to 
the individual patient's symptom complex. Hyperactive re-
sponse to carotid sinus stimulation is defined as asystole due 
to sinus arrest or A V block of more than 3 s or a substantial 
symptomatic decrease in systolic blood pressure, or both. 
Such heart rate and hemodynamic responses may occur in 
normal subjects and patients with coronary artery disease 
(46,47); a conclusion of a cause and effect relation between 
the hypersensitive carotid sinus and the patient's symptoms 
must be made with great caution. Spontaneous syncope that 
is then reproduced by carotid sinus stimulation should alert 
the physician to the presence of this syndrome. Minimal 
pressure on the carotid sinus in elderly patients or patients 
receiving digitalis may result in marked changes in heart rate 
and blood pressure, yet not be of clinical significance. 
Permanent pacing for patients with pure excessive cardioin-
hibitory response to carotid stimulation is effective in reliev-
ing symptoms (48-50). Because 10% to 20% of patients with 
this syndrome may have an important vasodepressor com-
ponent of their reflex response, it is necessary to define this 
component before concluding that all symptoms are related 
to asystole alone. In patients whose reflex response includes 
both cardioinhibitory and vasodepressor components, atten-
tion to the latter is essential for effective therapy in patients 
undergoing permanent pacing. 
DREIFUS ET AL. 
ACC/AHA TASK FORCE REPORT 
Indications for Permanent Pacing in 
Hypersensitive Carotid Sinus and 
Neurovascular Syndromes 
Class I 
5 
A. Recurrent syncope associated with clear, spontane-
ous events provoked by carotid sinus stimulation; 
minimal carotid sinus pressure induces asystole of 
> 3 s duration in the absence of any medication that 
depresses the sinus node or A V conduction. 
Class II 
A. Recurrent syncope without clear, provocative 
events and with a hypersensitive cardioinhibitory 
response. 
B. Syncope with associated bradycardia reproduced by 
a head-up tilt with or without isoproterenol or other 
forms of provocative maneuvers and in which a 
temporary pacemaker and a second provocative test 
can establish the likely benefits of a permanent 
pacemaker (51). 
Class III 
A. A hyperactive cardioinhibitory response to carotid 
sinus stimulation in the absence of symptoms. 
B. Vague symptoms, such as dizziness or light-
headedness, or both, with a hyperactive cardioinhib-
itory response to carotid sinus stimulation. 
C. Recurrent syncope, light-headedness or dizziness in 
the absence of a cardioinhibitory response. 
VII. Use of Pacemakers in Children 
Although the indications for pacemakers in children are 
similar to those in adults, there are some special consider-
ations. As in the adult, the optimal indication for pacemaker 
implantation in a child is the concurrent observation of 
symptoms with bradycardia-for example, syncope and 
complete A V block or syncope with severe bradycardia (30 
beats/min). Concurrence of symptoms and bradycardia can 
be determined by 24 h ambulatory electrocardiography or 
transtelephonic electrocardiography. 
Sinus node dysfunction (sick sinus syndrome), although 
becoming more frequently recognized in pediatric patients, 
is not in and of itself an indication for pacemaker implanta-
tion. In patients with sinus node dysfunction even greater 
emphasis is placed on concurrence of sinus bradycardia or 
exit block with symptoms. Symptomatic bradycardia (as 
defined in the Introduction) with sinus node dysfunction is 
considered to be an indication for a pacemaker, assuming 
that another cause of such symptoms has been excluded. 
Such alternative causes to be considered include seizures, 
breath holding, infantile apnea and autonomic dysfunction. 
The bradycardia-tachycardia syndrome is frequently an 
indication for a pacemaker in children, particularly if an 
antiarrhythmic drug other than digitalis is necessary. The 
use of quinidine or other type I drugs is particularly danger-
ous in children with this syndrome. Propranolol and amio-
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darone also severely depress sinus node function and their 
use may require pacing in children with the bradycardia-
tachycardia syndrome. 
Indications for Permanent Pacing in Children 
Class I 
A. Second or third degree A V block with symptomatic 
bradycardia, as defined. 
B. Advanced second or third degree A V block with 
moderate to marked exercise intolerance. 
C. External ophthalmoplegia with bifascicular block 
(52). 
D. Sinus node dysfunction with symptomatic bradycar-
dia, as defined. 
E. Congenital A V block with wide QRS escape rhythm 
or with block below the His bundle (53). 
F. Advanced second or third degree AV block persist-
ing 10 to 14 days after cardiac surgery (54). 
Class II 
A. Bradycardia-tachycardia syndrome with need for an 
antiarrhythmic drug other than digitalis or phenytoin 
(55,56). 
B. Second or third degree A V block within the bundle 
of His in an asymptomatic patient (54). 
C. Prolonged subsidiary pacemaker recovery time (57). 
D. Transient surgical second or third degree A V block 
that reverts to bifascicular block (58). 
E. Asymptomatic second or third degree A V block and 
a ventricular rate <45 beats/min when awake (59). 
Complete A V block when awake, with an average 
ventricular rate <50 beats/min (60). 
F. Complete A V block with double or triple rest cycle 
length pauses or minimal heart rate variability. 
G. Asymptomatic neonate with congenital complete 
heart block and bradycardia in relation to age (61). 
H. Complex ventricular arrhythmias associated with 
second or third degree A V block or sinus bradycar-
dia (60,62). 
I. Long QT syndrome. 
Class III 
A. Asymptomatic, postoperative bifascicular block. 
B. Asymptomatic postoperative bifascicular block with 
first degree A V block. 
C. Transient surgical A V block that returns to normal 
conduction in < 1 week. 
D. Asymptomatic type I second degree A V block. 
E. Asymptomatic congenital heart block without pro-
found bradycardia in relation to age. 
VIII. Pacing for Tachyarrhythmia 
The decision to use a pacemaker to control tachycardias 
should be made only after careful observation and electro-
physiologic study by those experienced in this complex field. 
Indications for Permanent Pacing 
for Tachyarrhythmias 
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Under certain circumstances an implanted pacemaker 
may be useful in the treatment of patients with recurrent 
symptomatic ventricular and supraventricular tachycardias 
(63-75). Reentrant rhythms may be interrupted by a variety 
of pacing patterns including programmed stimulation and 
short bursts of rapid pacing (76,77). These antitachyarrhyth-
mia devices may detect tachycardia and automatically acti-
vate a pacing sequence or they may respond only to an 
external instruction-for example, application of a magnet. 
In some patients with the long QT syndrome, recurrent 
ventricular tachycardia may be prevented by continuous 
pacing (78). Atrial synchronous ventricular pacing may 
prevent recurrences of reentrant supraventricular tachycar-
dia. Although ventricular ectopic activity may be suppressed 
by such pacing in other conditions, serious or symptomatic 
arrhythmias are rarely prevented (79). 
Potential recipients of antitachyarrhythmia devices that 
interrupt arrhythmias should undergo extensive testing be-
fore implantation to ensure that the devices safely and 
reliably terminate the ectopic mechanism without accelerat-
ing the tachycardia or inducing ventricular fibrillation. These 
patients usually have been unresponsive to antiarrhythmic 
drugs or were receiving agents that were inappropriate to 
control the cardiac arrhythmias. When permanent pacemak-
ers employing programmed extrastimulation or rapid over-
drive pacing are used to detect and interrupt supraventricu-
lar tachycardia, all pacing should be done in the atrium. 
Although these pacemakers may be effective, adverse inter-
actions have been reported (65,80) with use of ventricular 
pacing to interrupt supraventricular arrhythmias. 
Indications for Permanent Pacemakers 
That Automatically Detect and Pace to 
Terminate Tachycardias 
Class I 
A. Symptomatic recurrent supraventricular tachycar-
dia when drugs fail to control the arrhythmia or 
produce intolerable side effects. 
B. Symptomatic recurrent ventricular tachycardia after 
an automatic defibrillator has been implanted or 
incorporated in the device and recurrence of ventric-
ular tachycardia is not prevented by drug therapy or 
when no other therapy is applicable. 
Class II 
A. Recurrent supraventricular tachycardia as an alter-
native to drug therapy. 
Class III 
A. Tachycardias that are accelerated or converted to 
fibrillation by pacing. 
B. The presence of accessory pathways having the 
capacity for rapid anterograde conduction whether 
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or not the pathways participate in the mechanism of 
the tachycardia. 
Indications for Externally Manually Activated 
Antitachyarrhythmia Devices That Act to 
Terminate Tachycardia 
Class I 
A. Recurrent, symptomatic ventricular tachycardia un-
controlled by drugs when surgery, catheter ablation 
or the implantation of an automatic pacemaker or 
cardioverter-defibrillator is not indicated. 
Class III 
A. Recurrent tachycardia that produces syncope. 
Indications for Overdrive or Atrial Synchronous 
Ventricular Pacemakers Intended to Prevent 
Tachycardia Occurrence 
Class I 
A. Atrioventricular reentrant or A V node reentrant 
supraventricular tachycardia not responsive to med-
ical therapy. 
Class II 
A. Sustained ventricular tachycardia in other condi-
tions when all other therapies are ineffective or 
inapplicable and efficacy of pacing is thoroughly 
documented. 
B. Long QT syndrome. 
Class III 
A. Frequent or complex ventricular ectopic activity 
without sustained ventricular tachycardia associated 
with coronary artery disease, cardiomyopathy, mi-
tral valve prolapse; or a normal heart and in the 
absence of the long QT syndrome. 
B. The long QT syndrome due to remediable causes. 
IX. Indications for Implantation of 
Automatic Defibrillator Devices 
Early clinical reports suggest that an automatic implanted 
cardioverter-defibrillator is effective in preventing sudden 
cardiac death in patients presumed to be at risk for life-
threatening ventricular tachyarrhythmias. Subsequent expe-
rience (81-88) continues to support these impressions. There 
have been no prospective randomized studies comparing this 
or other devices to other treatments but several less rigorous 
comparisons have been published (89-91). 
Concern remains about the value of drug therapy for 
preventing ventricular fibrillation and sudden death. Unfor-
tunately there is still no complete evidence that drug therapy 
aimed at ventricular arrhythmias reduces the incidence of 
sudden death due to coronary heart disease. However, the 
prognosis of repeated ventricular tachycardia or ventricular 
tachyarrhythmia resistant to therapy with antiarrhythmic 
drugs is known to be poor; patients so affected frequently die 
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suddenly (92-96). By comparison, survival in patients 
treated with the implanted cardioverter-defibrillator is quite 
favorable (97). The actuarial survival of patients receiving 
these devices was compared with the projected survival rate 
if the first clinically appropriate shock had been ineffective. 
Two such studies (98,99) showed significant improvements 
in survival in patients with the defibrillator. However, this 
study design tends to overestimate mortality because some 
shocks might have been untriggered or might have inter-
rupted an arrhythmia that would not have been lethal. 
Another study (100) using concurrent medically treated 
populations for comparison showed a better outcome in 
subjects with the implanted cardioverter-defibrillator. 
A special case for consideration is the patient with a 
documented episode of aborted sudden death who does not 
have an inducible tachyarrhythmia at electrophysiologic 
study. In patients surviving an episode of sudden cardiac 
death due to ventricular tachycardia or fibrillation, invasive 
electrophysiologic testing with programmed stimulation can 
be used to define therapy if ventricular arrhythmias are 
inducible. In a significant fraction of patients with aborted 
sudden death, clinical ventricular arrhythmias are not induc-
ible by accepted laboratory protocols (94-96). Thus, it is not 
possible to estimate the true relative risks. It is clear that 
despite therapy, sudden death is relatively common in pa-
tients with inducible tachyarrhythmias; 14% died suddenly 
at a mean follow-up interval of 20 months. 
Another special case is the patient in whom it is not 
possible to predict subsequent efficacy of therapy by ambu-
latory ECG monitoring, electrophysiologic study or other 
methods. This situation occurs under three circumstances in 
which a "fail safe" therapy such as an implanted cardio-
verter-defibrillator is reasonable: 
1. Tachyarrhythmia is not inducible and spontaneous 
ventricular ectopic activity is infrequently observed or 
absent. 
2. Previous predictions of efficacy were incorrect. 
3. Efficacy assessment is contraindicated, refused or in-
feasible. 
Before a patient is considered to be a candidate for an 
implanted defibrillator, the arrhythmia in question must have 
been demonstrated to be life threatening, producing sudden 
death, syncope or severe hemodynamic compromise. Reme-
diable causes of the arrhythmia must have been ruled out, 
such as acute myocardial infarction, myocardial ischemia, 
electrolyte imbalance and drug toxicity. Device selection 
mandates the participation of an electrophysiologist. Indica-
tions for implanted cardioverter-defibrillator implantation 
remain evolutionary and controversial. Therefore, these 
guidelines are fairly liberal pending further definitions (101). 
Class I 
A. One or more documented episodes of hemodynam-
ically significant ventricular tachycardia or ventric-
ular fibrillation in a patient in whom electrophysio-
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logic testing and ambulatory monitoring cannot be 
used to accurately predict efficacy of therapy. 
B. One or more documented episodes of hemodynam-
ically significant ventricular tachycardia or ventric-
ular fibrillation in a patient in whom no drug was 
found to be effective or no drug currently available 
and appropriate was tolerated. 
C. Continued inducibility at electrophysiologic study of 
hemodynamically significant ventricular tachycardia 
or ventricular fibrillation despite the best available 
drug therapy or despite surgery or catheter ablation 
if drug therapy has failed. 
Class II 
A. One or more documented episodes of hemody-
namically significant ventricular tachycardia or 
ventricular fibrillation in a patient in whom drug 
efficacy testing is possible. 
B. Recurrent syncope of undetermined origin in a 
patient with hemodynamically significant ventric-
ular tachycardia or ventricular fibrillation in-
duced at electrophysiologic study in whom no 
effective or no tolerated drug is available or 
appropriate. 
Class III 
A. Recurrent syncope of undetermined cause in a pa-
tient without inducible tachyarrhythmias. 
B. Arrhythmias not due to hemodynamically significant 
ventricular tachycardia or ventricular fibrillation. 
C. Incessant ventricular tachycardia or fibrillation. 
x. Clinical Applications of Various Pacing 
Modes and Device Selection 
This section lists the conditions for which various pacing 
modes might be selected. The acceptability of a given mode 
of pacing is divided into three classes according to the 
following definitions: 
Class I: Conditions for which there is general 
agreement that such a mode of pacing is 
appropriate. 
Class II: Conditions for which a given mode of 
pacing may be used but there is divergence 
of opinion with respect to the necessity of 
that mode of pacing. 
Class III: Conditions for which there is general 
agreement that such a mode of pacing is 
inappropriate. 
Two varieties of pulse generators are available for per-
manent implantation: 
1. Single chamber pacemakers for use in either atrium or 
ventricle. 
2. Dual chamber pacemakers for use in both atrial and 
ventricular chambers (usually programmable to single 
chamber pacemaker modes as well). 
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Virtually all modem pacemakers are multiprogrammable, 
which renders them more or less adaptable to changing 
clinical situations. (Some pacing modes that were originally 
found as specific pacemaker models, such as ventricular 
asynchronous pacing mode (YOO), P wave synchronized 
pacing mode (VAT) and ventricular-triggered pacing mode 
(VYT) , and that still retain some useful, though minor, 
functions are not discussed [102]. These modes are optional 
settings of some multiprogrammable pacemakers.) Many 
new pacemakers provide telemetry of stored and variable 
data that, on command, can provide information about 
pacemaker function and clinical performance. Both pro-
grammability and telemetry are helpful in optimizing pace-
maker function, avoiding reoperation and extending pulse 
generator life. 
Many pacemakers also incorporate alternate sensors that 
respond to variables (signals) other than P waves to increase 
the pacing rate (102). Adaptive rate pacemakers (rate mod-
ulated, "rate responsive") utilize various types of sensors 
that respond to physical, chemical or electrical signals. They 
can be classified roughly in the following way: 
A. Physical 
1. Motion-physical activity. 
2. Temperature-mixed right atrial venous-blood tem-
perature. 
B. Chemical 
1. Venous oxygen saturation. 
2. pH. 
C. Electrical phenomena 
1. Impedance variations-respiratory rate, minute ven-
tilation, right ventricular stroke volume, rate of 
change of right ventricular pressures and stroke 
volume (dP/dt and dV/dt) and preejection period. 
2. Intracardiac potentials 
a. Stimulus to T wave intervals. 
b. Evoked potentials (Wilson's ventricular depolar-
ization gradient). 
Single chamber pacemakers incorporating at least one of 
these alternate variables are widely used. Alternate sensors 
also have been added to dual chamber devices. Pacemakers 
using two variables in addition to the P wave are also making 
their appearance. 
Adaptive rate pacemakers cost more than their nonadap-
tive equivalents. They may require special electrodes and 
leads that are not compatible with preexisting or future 
models. 
Some believe that single chamber adaptive rate pacemak-
ers are equivalent to standard dual chamber pacemakers in 
terms of physiologic effectiveness. Although this may be less 
important at rapid heart rates, at slow heart rates it is almost 
always desirable to maintain AY synchrony. Long-term 
absence of A V synchrony increases the incidence of atrial 
fibrillation and stroke and may reduce patient life expect-
ancy, particularly in patients with impaired ventricular func-
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tion, idiopathic hypertrophic subaortic stenosis or aortic 
stenosis (103-108). Therefore, the concept that the single 
chamber pacemaker with adaptive-rate functions is equiva-
lent to the dual chamber pacemaker cannot be supported as 
a general rule. 
In choosing between pacemakers with or without adap-
tive rate functions, the following factors should be consid-
ered: 
1. The cardiac conduction abnormality. 
2. The nature and severity of comorbidities. 
3. The presence of coronary heart disease and angina 
pectoris. 
4. The degree of left ventricular dysfunction. 
5. The impact of present and future drug therapy. 
6. The level of anticipated activity. 
7. The availability of support services, such as follow-up 
clinics, industrial backup and availability. 
8. The expertise of implant teams familiar with the device 
and its programmable function. 
9. Costs. 
The primary indication for an adaptive rate pacemaker is 
to permit a heart rate increase in the absence of an appro-
priate spontaneous increase in heart rate. This may be the 
case if the P waves are undetectably small, or absent as in 
atrial fibrillation, or are unresponsive to stress or exercise. 
The latter condition has come to be known as chronotropic 
incompetence (109). For practical purposes chronotropic 
incompetence might be said to exist if the heart rate does not 
reach 100 beats/min in response to an exercise test. 
There are advantages and disadvantages to each; perhaps 
the most important consideration is whether there is a need 
for a special lead. Devices that may be used with standard 
unipolar or bipolar electrodes are those that sense the 
stimulus to T wave interval, evoked potentials, vibration, 
ventricular preejection period and ventricular volume 
change. Conditions that require special electrodes are tem-
perature, oxygen saturation, dP/dt and ventricular pressure. 
The characteristics of the variables to be considered are 
input and output feedback (closed or open loop), speed of 
rate response and rate of recovery, appropriateness of the 
rate response to the activity, the susceptibility of the sensor 
to extraneous signals ("noise"), the complexity of program-
ming and follow-up, the projected influence on power con-
sumption and the longevity of the battery. 
Many pulse generators incorporate other adaptive func-
tions. These include differing A V intervals after a paced or 
sensed P wave, shortening of the A V interval and the atrial 
refractory period with increasing heart rate or metabolic 
activity, extension of the atrial refractory period after a 
ventricular premature beat to prevent sensing of retrograde 
atrial activity and rate-smoothing adaptation for manage-
ment of irregular atrial rates. Furthermore, some specialized 
pacemakers also can be utilized for noninvasive electrophys-
iologic and antiarrhythmic studies. Clearly, further data are 
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needed to identify the relative benefit of these adaptive 
functions. The physician must decide how many of these 
features, if any, are clinically necessary. It is assumed that 
pacemakers will be implanted by experts who are able to 
select the device that offers the best clinical advantage at 
reasonable cost. 
Single Chamber Pacemakers 
I. Atrial-AAI: Atrial pacing inhibited by sensed atrial 
activity 
Class I 
A. Symptomatic sinus node dysfunction (sick sinus 
syndrome), provided AV conduction is shown to 
be adequate by appropriate studies. 
Class II 
A. Hemodynamic enhancement through rate adjust-
ment in patients with bradycardia and symptoms 
of impaired cardiac output, provided A V conduc-
tion is shown to be adequate by appropriate tests. 
Class III 
A. Preexisting A V conduction delay or block or if 
decremental A V conduction is demonstrated by 
appropriate tests. 
B. Inadequate intracavitary atrial complexes. 
AAIR*: As in class I and II but with chronotropic 
incompetence and an anticipated moderate 
to high level of physical activity, normal A V 
conduction and with little likelihood of pro-
gression of A V block or induction of A V 
block as the result of drug therapy (110). 
II. Ventricular-VVI: The classic prototypical pacing 
mode; ventricular pacing inhibited by sensed sponta-
neous ventricular activity. 
Class I 
A. Any symptomatic bradyarrhythmia but particu-
larly when there is: 
1. No significant atrial hemodynamic contribution 
(persistent or paroxysmal atrial flutter/fibril-
lation, giant atria). 
2. No evidence of pacemaker syndrome due to 
loss of atrial contribution or negative atrial 
kick (a replacement pacemaker). t 
* Atrial pacing inhibited by sensed atrial activity. R in position 4 indicates 
the presence of an adaptive rate function. 
tThe pacemaker syndrome was first defined as light-headedness or 
syncope related to long periods of A V asynchrony that occurred at times 
during ventricular-inhibited (VVI) or VOO pacing (111). The definition is now 
expanded to include 1) episodic weakness or syncope associated with alter-
nating AV synchrony and asynchrony; 2) inadequate cardiac output associ-
ated with continued absence of A V synchrony or with fixed asynchrony 
(persistent V A conduction); and 3) patient awareness of beat to beat varia-
tions in cardiac contractile sequence, often as a result of a) cannon A waves, 
b) V waves transmitted to the atria or pulmonary veins, and c) bundle branch 
block patterns of ventricular contraction with a paced beat. 
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Class II 
A. Symptomatic bradycardia where pacing simplicity 
is a prime concern in cases of: 
1. Senility (for life-sustaining purposes only). 
2. Terminal disease. 
3. Domicile remote from a follow-up center. 
4. Absent retrograde ventriculoatrial (V A) con-
duction. 
Class III 
A. Known pacemaker syndrome or symptoms pro-
duced by temporary ventricular pacing at the time 
of initial pacemaker implantation 
B. The need for maximum atrial contribution because 
of 
I. Congestive heart failure. 
2. Special need for rate response. 
VVIR*: As in class I and II but with chronotropic 
incompetence and anticipated moderate to 
high level of physical activity. VVIR pace-
makers are particularly contraindicated in 
the presence of retrograde V A conduction or 
when angina pectoris or congestive failure is 
aggravated by fast rates. 
Dual Chamber Pacemakers 
I. VDD: Ventricular pacing in synchrony with sensed 
atrial activity inhibited by sensed ventricular activity. 
(Although these units are rate modulated at a slow atrial 
rate below the set rate of the pacemaker, only the 
ventricle is paced, in which case the pacemaker func-
tions as a VVI unit.) With the recent development of 
"single pass" leads that incorporate ventricular pacing 
electrodes at the tip and a set of sensing electrodes in 
the right atrium on the shaft of the lead, this mode has 
regained some popularity (112). This system does not 
provide atrial pacing. 
Class I 
A. Requirements for ventricular pacing when ade-
quate atrial rates and adequate intracavitary atrial 
complexes are present. This includes the presence 
of complete A V block when 
I. Atrial contribution is needed for hemodynamic 
benefit. 
2. Pacemaker syndrome had existed or is antici-
pated. 
Class II 
A. Normal sinus rhythm and normal AV conduction 
in patients needing ventricular pacing intermit-
tently. 
Class III 
A. Frequent or persistent supraventricular tachyar-
*Ventricular-VVIR: The classic prototypical pacing mode; ventricular 
pacing inhibited by sensed spontaneous ventricular activity. R in position 4 
indicates the presence of adaptive rate function. 
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rhythmias, including atrial fibrillation or flutter. 
B. Inadequate intracavitary atrial complexes. 
C. Intact V A conduction. 
II. DVI: Pacing of both chambers at a preselected rate 
with both outputs inhibited by ventricular but not atrial 
complexes. t 
Class I 
A. The need for synchronous atrial-ventricular con-
traction in symptomatic bradycardia and a slow 
atrial rate. 
B. Previously documented pacemaker syndromes. 
Class II 
A. Frequent supraventricular arrhythmias in which 
combined pacing and drugs have been shown to 
be therapeutically effective. 
B. Bradycardia-tachycardia syndrome, provided ad-
justment of atrial rate and A V interval terminates 
or prevents the emergence of supraventricular 
arrhythmias with or without concomitant drug 
administration. 
Class III 
A. Frequent or persistent supraventricular tachyar-
rhythmias, including atrial fibrillation or flutter. 
DVIR: An option in some adaptive rate pacemakers. 
There is no atrial sensing and therefore atrial 
synchrony at fast rates does not occur. 
III. DDI: Dual chamber pacing, sensing in both chambers 
and inhibited by sensed events in both chambers. This 
mode is like DDD and DVI pacing in that it provides 
A V synchrony at slow rates (113). It is unlike DDD 
pacing in that there is no atrial tracking and unlike 
DVI pacing in that the atrial output will be inhibited 
by an atrial or ventricular event, thus avoiding the 
provocation of an atrial arrhythmia through competi-
tive pacing. Thus, it is useful in patients requiring dual 
chamber pacing who have frequent, but not constant, 
supraventricular arrhythmias. 
DDIR: A particularly useful mode in chronotropic 
incompetence when a moderate to high level 
of activity is anticipated and when there are 
fairly frequent atrial arrhythmias or in those 
individuals who need dual chamber pacing 
intermittently. 
IV. DDD: Pacing of both chambers, sensing of both 
chambers, inhibition of atrial or ventricular output 
by sensed atrial or ventricular activity; triggering of 
ventricular output by sensed atrial activity. 
Class I 
A. Requirement for A V synchrony over a wide range 
of rates such as 
1. The active or young patient with atrial rates 
responsive to clinical need. 
tThis mode, in providing no atrial sensing, is rarely needed now that more 
"physiologic" dual-chamber modes are available. 
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2. Significant hemodynamic need. 
3. Pacemaker syndrome during previous pace-
maker experience or a reduction in systolic 
blood pressure >20 mm Hg during ventricular 
pacing at the time of pacemaker implantation 
(with or without evidence of V A conduction). 
Class II 
A. Complete heart block or sick sinus syndrome and 
stable atrial rates. 
B. When simultaneous control of atrial and ventricu-
lar rates can be shown to inhibit tachyarrhythmias 
or when the pacemaker can be adjusted to a mode 
designed to interrupt the arrhythmia. 
Class III 
A. Frequent or persistent supraventricular tachyar-
rhythmias, including atrial fibrillation or flutter. 
B. Inadequate intracavitary atrial complexes. 
C. Angina pectoris aggravated by rapid heart rates. 
DDDR: This mode is indicated in patients with chron-
Comment 
otropic incompetence who have an antici-
pated moderate or high level of activity and 
in whom there is a stable atrial rhythm. It is 
particularly applicable in those patients who 
have persistent V A conduction. 
Pacemakers have grown immensely complex, rendering 
interpretation of the paced electrocardiogram difficult for 
even the most experienced cardiologist. The subtleties of 
indications, device selection and, especially, follow-up re-
quire constant study and hands-on usage. Thus, pacing 
should be performed by individuals with appropriate training 
who maintain their skills by participating in an adequate 
number of operations (3). 
The implanting physician must also assure that patients 
receive regular follow-up care in a facility in which special 
attention is paid to the adequacy of pacemaker function and 
to its optimal physiologic effectiveness (114). Simple ECG 
monitoring or transtelephonic transmission of signals from 
complex pacemakers at the present state of the art in 
themselves are not satisfactory surveillance methods. 
Some implanters use sales and other industrial represen-
tatives to assist them with their implantations. The sales 
representatives thus act as hospital technicians and may not 
be adequately protected by liability insurance. It is a practice 
that should not be condoned (115). 
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